During the podium presentation,
Before the presentation,
iBio's Drug Discovery Platform is a precision-driven and deeply integrated technology stack that aims to efficiently and consistently deliver antibody candidates against challenging targets and move them into the clinic faster. The Company uses its technology to advance candidates with partners and collaborators, and for its own proprietary pipeline.
About
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
FORWARD LOOKING STATEMENTS
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the Company’s patented AI-powered tech stack, including EngageTx and ShieldTx, offering an accelerated solution to generating bispecific antibodies, the Company’s technology overcoming challenges in the discovery of bispecific T-cell engagers, the Company’s machine learning epitope steering and mammalian-display antibody library efficiently discovering diverse T-cell engager arms turned for potency, toxicity, developability, and cyno cross-reactivity, and our technology having the ability can optimize next-gen CD3-T cell engager bispecifics. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to execute its growth strategy; its ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications; acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products; competition; the Company’s ability to retain its key employees or maintain its NYSE American listing; and the other factors discussed in the Company’s filings with the
Contact:
Investor Relations
(646) 274-3580
skilmer@ibioinc.com
Media Relations
(619) 540-9195
susan.thomas@ibioinc.com
Source:
2024 GlobeNewswire, Inc., source